Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Conditions: Chronic Allograft Dysfunction
Interventions: STX-100; Biological
Lead sponsor: Stromedix, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
Interventions: setrusumab, Calcium, Vitamin D, zoledronic acid (optional); Drug · Dietary Supplement
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more

Conditions: Healthy Participants
Interventions: AZD3974, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: AZD5055, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Scabies
Interventions: Moxidectin Oral Product, Placebo; Drug
Lead sponsor: Medicines Development for Global Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida

Conditions: COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions: TXA127, TRV027, Placebo, Fostamatinib; Drug
Lead sponsor: Sean Collins; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 51
States / cities: Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more

Conditions: Nerve Injury
Interventions: Temporary Peripheral Nerve Stimulation System, Sham Temporary Peripheral Nerve Stimulation System; Device
Lead sponsor: Epineuron Technologies Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Gainesville, Florida • Orlando, Florida • New Orleans, Louisiana + 3 more

Conditions: Alzheimer Disease
Interventions: TB006, Sterile saline (Placebo); Drug · Other
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Safety, Pharmacokinetics, Pharmacodynamics
Interventions: Kratom, Placebo; Drug
Lead sponsor: Altasciences Company Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity, Overweight
Interventions: LY4329090, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Migraine Disorders
Interventions: LY2951742, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions: Faricimab Injection, sham treatment; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COVID-19, Sars-CoV-2 Infection
Interventions: NVX-CoV2705, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 50 Years to 65 Years
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 99
States / cities: Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more

Conditions: Respiratory Depression
Interventions: Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more

Conditions: Healthy Men, Male Contraception
Interventions: Dimethandrolone Undecanoate, Placebo; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Healthy Subjects
Interventions: CDX-0159, Normal saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Alcohol Use Disorder
Interventions: Diclofenac, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Influenza
Interventions: Flufirvitide 3, Placebo for Flufirvitide-3; Drug
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Richard Barohn, MD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more

Conditions: Healthy
Interventions: ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Search by objective public record fields.

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Efficacy and Safety Study of Moxidectin in Adults With Scabies

Novel Experimental COVID-19 Therapies Affecting Host Response

Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Efficacy and Safety of NVX-CoV2705

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Diclofenac as a KMO Inhibitor

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis